Global Blood Screening Market By Technology (Nucleic Acid Amplification Test (NAT), ELISA, Chemiluminescence Immunoassay (CLIA) & Enzyme Immunoassay (EIA), Next Generation Sequencing, and Western Blotting), By Product (Reagent and Instrument), By End-user (Independent Clinical Laboratories, Hospital-based Laboratories, and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The Global Blood Screening Market size is expected to be worth around USD 6.4 billion by 2033 from USD 2.7 billion in 2023, growing at a CAGR of 9.0% during the forecast period 2024 to 2033.

Blood screening is a crucial process where donated blood undergoes testing to detect infectious diseases such as HBV, HCV, HIV1, and HIV2. The growth of this market can be attributed to increased blood donations, a higher incidence of infectious diseases, and government initiatives.

According to the World Health Organization (WHO) report published in June 2023, approximately 118.54 million blood donations are collected annually. In the United States, around 6.8 million individuals donate blood each year, resulting in the collection of 13.6 million units of red blood cells and whole blood. The market’s momentum is driven by the rising prevalence of disorders like HIV, measles, diphtheria, and chronic conditions such as hemophilia and cancer.

Blood-based diagnostics play a vital role in diagnosing various health issues, including cancer, infectious diseases, and cardiovascular disorders. Serology tests detect specific antibodies related to disease-causing organisms, while molecular tests identify DNA or RNA from pathogens. Additionally, biochemical tests measure specific substances in the blood, aiding in the diagnosis of conditions like kidney disease, diabetes, and liver disorders.

Key Takeaways

• Market Size: Blood Screening Market size is expected to be worth around USD 6.4 billion by 2033 from USD 2.7 billion in 2023.
• Market Growth: The market growing at a CAGR of 9.0% during the forecast period 2024 to 2033.
• Technology Analysis: The nucleic acid amplification test (NAT) segment led in 2023, claiming a market share of 33.4%
• Product Analysis: The reagent held a significant share of 65.2% and is expected to grow at the fastest CAGR.
• End-Use Analysis: The independent clinical laboratories segment had a tremendous growth rate, with a revenue share of 48.2%
• Regional Analysis: North America led the market by securing a market share of 5% in 2023.

By Technology Analysis

The nucleic acid amplification test (NAT) segment led in 2023, claiming a market share of 33.4% owing to its high specificity and sensitivity for detecting viral nucleic acid. NAATs can identify nucleic acid faster than other screening methods, narrowing the window period for HCV, HBV, and HIV.

As per the World Health Organization (WHO), HIV has taken 40.1 million lives to date and remains a health concern across the globe, with ongoing transmission in all countries. In 2021 alone, 1.5 million people acquired HIV.

By Product Analysis

The reagent held a significant share of 65.2% and is expected to grow at the fastest compound annual growth rate during the forecast period. Reagents play a crucial role in blood screening by detecting the presence and type of various elements in small samples. These reagents include chemical, biological, or immunological products used in the blood screening process.

Their accuracy and specificity contribute to their popularity, and they offer cost-effectiveness for customers and high returns on investment for vendors.

By End-user Analysis

The independent clinical laboratories segment had a tremendous growth rate, with a revenue share of 48.2%. The increasing number of stand-alone clinical laboratories in both developed and emerging countries, along with substantial investments in infrastructure, has led to a rise in blood screening procedures.

Partnerships between blood centers and independent clinical laboratories further drive the adoption of blood screening tests in these settings, contributing to the overall growth of the blood screening market during the forecast period.

Key Market Segments

By Technology

• Nucleic Acid Amplification Test (NAT)
• ELISA
• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
• Next Generation Sequencing
• Western Blotting

 By Product

• Reagent
• Instrument

 By End-user

• Independent Clinical Laboratories
• Hospital-based Laboratories
• Others

Drivers

Rising Prevalence of Chronic Diseases and Government Initiatives

The rising prevalence of chronic diseases and government initiatives are driving the requirement for blood screening. As diseases like cancer, cardiovascular conditions, and infectious diseases become more common globally, early detection & proactive healthcare measures are essential. Routine screenings enable well-timed management and intervention of health issues.

Government efforts, such as implementing screening programs and promoting regular health check-ups, further contribute to this demand. The public health campaigns, supportive healthcare policies, and strategic investments enhance awareness and accessibility to blood screening services, ultimately improving public health outcomes.

According to the data published by the World Health Organization in September 2023, chronic ailments such as cardiovascular diseases are responsible for the most number of non-communicable diseases (NCD) deaths each year, equating to 17.9 million deaths annually. This is followed by various cancers (almost 9.3 million deaths), and chronic respiratory diseases (around 4.1 million deaths).

Restraints

Ethical and Infrastructure Challenges

Ethical concerns and infrastructure limitations significantly impact the blood screening market. Worries about genetic information usage may cause hesitancy among individuals, affecting their willingness to go through certain blood tests. Additionally, fears of discrimination built on screening results create hesitations about participation in screening programs.

In developing regions, inadequate healthcare infrastructure hinders the seamless incorporation of advanced technologies for blood screening. Limited access to screening services, especially in rural areas with scarce diagnostic tools and trained professionals, exacerbates the issue. Addressing these infrastructural and ethical barriers is crucial for reasonable access to blood screening services and maximizing the benefits of early disease prevention and detection.

Opportunities

Increase Use of Disease-Specific Screening Programs in Blood Screening

The increasing use of disease-specific screening programs presents an opportunity for the blood screening market by driving demand for specialized blood tests. These programs require targeted blood screening to identify high-risk individuals, fueling growth in the market. Diaease-specific screening programs also raise awareness about the importance of blood screening, leading to increased adoption.

Furthermore, the advancements in blood screening technologies enable more accurate and efficient testing, thereby supporting market expansion. The growing need for early disease detection and prevention, especially in ailments such as cancer and Alzheimer’s disease, further propels the demand for blood screening. Overall, disease-specific screening programs create a significant opportunity for the blood screening market by increasing testing volumes and driving innovation.

In July 2023, Quest Diagnostics launched the AD-Detect test. This consumer-purchased blood test assesses the risk of developing Alzheimer’s disease by analyzing a brain protein. It offers a simpler alternative to PET imaging and CSF sampling for early detection of AD risk.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical factors exert a significant influence on the blood screening market, shaping its growth trajectory and dynamics. Macroeconomic factors such as government funding and investments in healthcare infrastructure drive the blood screening market. Geopolitical factors such as trade agreements and partnerships facilitate international collaborations and access to new markets.

Economic growth and stability lead to increased healthcare spending and market uncertainty. Despite healthcare, the focus on healthcare digitization and personalized medicine drives demand for advanced blood screening technologies.

Latest Trends

Growing Demand for Personalized Medicine

The growing demand for personalized medicine is driving the blood screening market, as tailored treatments require precise genetic and molecular profiling. Next Generation Sequencing (NGS) and other advanced technologies enable comprehensive blood screening for genetic variation. This information helps healthcare providers create targeted treatment plans, fueling demand for specialized blood tests.

Personalized medicine approaches, such as precision oncology, rely heavily on blood screening to identify biomarkers and monitor treatment response. As a result, the growing demand for high-sensitivity and high-specificity blood screening assays is increasing.

In 2023, the FDA approved 16 new personalized treatments specifically for rare disease patients, which is a significant increase from the six approvals in 2022. These newly approved personalized treatments also include seven drugs for cancer and three for other diseases and conditions.

Regional Analysis

North America is leading the Blood Screening Market

North America dominated the market with the highest revenue share of 37.5% owing to several factors. These include the presence of major industry players, widespread adoption of blood screening processes, strict FDA regulations for transfusion safety, and better affordability for patients. The U.S., with companies like Abbott, Roche Diagnostics, and Danaher, leads this market.

Established research and development infrastructure and favorable reimbursement policies contribute to their continued dominance. Additionally, the high prevalence of chronic diseases like diabetes and cancer drives the demand for blood screening. As per the American Cancer Society’s data published in 2022, close to 1,918,030 new cancer cases and around 609,360 deaths caused by cancer are projected to happen in the US.

The Asia Pacific region is expected to experience the highest CAGR during the forecast period

The Asia Pacific region is expected to experience the fastest growth in blood screening. Factors contributing to this include increased awareness about blood donation, improved affordability for patients, and industry focus on emerging countries. Key contributors in this region include India, Singapore, China, Japan, and Australia.

India stands out due to its unique market dynamics—more relaxed regulatory guidelines and significant imports of equipment and materials. Increased investments by private and foreign entities are driving growth, making effective tests more accessible at lower costs. India’s well-distributed network of clinical laboratories and hospitals also promotes faster adoption of blood screening techniques.

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Russia
• Netherland
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• Australia
• New Zealand
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Rest of MEA

Key Players Analysis

The major players in the blood screening market are actively engaged in the development and introduction of innovative products, as well as implementing strategic initiatives aimed at enhancing their competitive positioning. These market players invest heavily in product innovation and development, enhancing existing products and introducing new technologies.

They also focus on expanding market share, diversifying portfolios, and gaining access to new technologies. With partnerships and collaborations, they strengthen distribution networks, share expertise, and develop new products.

Top Key Players

• Abbott
• Siemens Healthcare
• Danaher Corporation (Beckman Coulter)
• Becton Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Hoffman-La Roche Ltd.
• Grifols, S.A.
• Thermo Fisher Scientific, Inc.
• Ortho-Clinical Diagnostics, Inc.
• BIOMÉRIEUX

Recent Developments

• In March 2023, Abbott received FDA clearance for a revolutionary laboratory test designed to analyze mild traumatic brain injuries (TBIs), also known as concussions. This lab-based test, powered by Abbott’s Alinity I laboratory tool, will be widely available in U.S. hospitals. Clinicians can now evaluate individuals with TBIs more efficiently.
• In May 2023, Siemens Healthcare, one of the key market players, launched the Atellica HEMA 570 and 580 next-generation hematology analyzers. These analyzers feature user-friendly interfaces and can be connected to multiple units, streamlining workflow and providing high throughput. They are designed to meet the testing needs of high-volume laboratories.

Report Scope